Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hangzhou Alltest Biotech Co., Ltd. specializes in the development and manufacturing of diagnostic instruments and supplies, primarily focusing on rapid testing solutions for infectious diseases. The company operates primarily in China, leveraging its advanced R&D capabilities and a strong distribution network to capture market share in the growing healthcare sector.
Alltest generates revenue through the sale of diagnostic testing kits and related instruments, benefiting from high gross margins due to proprietary technology and strong demand for rapid testing solutions. The company has established pricing power in a growing market driven by increasing health awareness and regulatory support for rapid diagnostics.
Regulatory approvals for new diagnostic tests
Market adoption rates of rapid testing solutions
Partnerships with healthcare providers and distributors
Changes in healthcare policies affecting diagnostic testing
Technological disruption from new diagnostic technologies
Regulatory changes impacting product approvals
Intensifying competition from both domestic and international diagnostic firms
Emerging players with innovative testing solutions
Limited financial flexibility due to low ROE and ROA
Potential liquidity issues if cash flow does not improve
moderate - The healthcare sector is generally resilient, but demand for diagnostic products can be influenced by economic conditions and consumer spending.
Minimal impact as the company is debt-free; however, rising rates could affect overall healthcare spending.
minimal
growth - Investors are likely attracted to the potential for rapid revenue growth in a high-demand sector.
high - The stock has shown significant volatility with a 1-year return of -28.0%.